The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol

被引:202
|
作者
Piper, Derek E.
Jackson, Simon
Liu, Qiang
Romanow, William G.
Shetterly, Susan
Thibault, Stephen T.
Shan, Bei
Walker, Nigel P. C. [1 ]
机构
[1] Amgen Inc, Dept Mol Struct, 1120 Vet Blvd, San Francisco, CA 94080 USA
[2] Amgen Inc, Dept Metab Disorders, San Francisco, CA 94080 USA
[3] Amgen Inc, Dept Prot Sci, San Francisco, CA 94080 USA
关键词
D O I
10.1016/j.str.2007.04.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been shown to be involved in the regulation of extracellular levels of the low-density lipoprotien receptor (LDLR). Although PCSK9 is a subtilase, it has not been shown to degrade the LDLR, and its LDLR-lowering mechanism remains uncertain. Here we report the crystal structure of human PCSK9 at 2.3 A resolution. PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal domain of PCSK9 has a novel protein fold and may mediate protein-protein interactions. The structure of PCSK9 provides insight into its biochemical characteristics and biological function.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 50 条
  • [31] Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
    Tavori, Hagai
    Melone, Michelle
    Rashid, Shirya
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (10) : 1137 - 1144
  • [32] STRUCTURE AND TRAFFICKING OF PCSK9 IN LDL BINDING
    Matteucci, Sara
    Pravata, Valentina
    Esposito, Francesco Maria
    Arnaboldi, Lorenzo
    Gianazza, Erica
    Grigore, Liliana
    Banfi, Cristina
    Catapano, Alberico
    [J]. ATHEROSCLEROSIS, 2024, 395
  • [33] Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering
    Bandyopadhyay, Dhrubajyoti
    Ashish, Kumar
    Hajra, Adrija
    Qureshi, Arshna
    Ghosh, Raktim K.
    [J]. JOURNAL OF LIPIDS, 2018, 2018
  • [34] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
    De Stefano, D.
    Baragetti, A.
    Baragetti, A.
    Macri, N.
    Tavori, H.
    Fazio, S.
    Catapano, A. L.
    [J]. ATHEROSCLEROSIS, 2018, 275 : E101 - E101
  • [35] New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol
    Meng, Fan-Hua
    Liu, Shuai
    Xiao, Jian
    Zhou, Yu-Xia
    Dong, Le-Wei
    Li, Yun-Feng
    Zhang, Yan-Qing
    Li, Wei-Hui
    Wang, Ju-Qiong
    Wang, Yan
    Song, Bao-Liang
    Ma, Yi-Tong
    Fu, Zhen-Yan
    Luo, Jie
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (07) : 1219 - 1233
  • [36] Multiple sequence variations in PCSK9 contribute to decreased plasma levels of LDL cholesterol
    Kotowski, IK
    Pertsemlidis, A
    Cohen, J
    Hobbs, HH
    [J]. CIRCULATION, 2005, 112 (17) : U412 - U412
  • [37] Antibodies to PCSK9 A Superior Way to Lower LDL Cholesterol?
    Maxwell, Kara N.
    Breslow, Jan L.
    [J]. CIRCULATION RESEARCH, 2012, 111 (03) : 274 - 277
  • [38] TRIAL WATCH PCSK9 antibody reduces LDL cholesterol
    Crunkhorn, Sarah
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (01) : 11 - 11
  • [39] PCSK9 Inhibitors The Magic Bullet for LDL Cholesterol Reduction?
    Richter, Kurt
    Barthel, Andreas
    Bornstein, Stefan R.
    El-Armouche, Ali
    Wagner, Michael
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 863 - U181
  • [40] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol REPLY
    Swergold, Gary D.
    Stein, Evan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2426 - 2426